Building on decades of pioneering research in ion channel biology and neurophysiology, our founders saw a clear path forward: from understanding how corpus cavernosa cells communicate to actively improving how blood flow function.
Recognizing the untapped therapeutic potential of well-known vasodilators like PDE5 inhibitors (sildenafil, tadalafil, and vardenafil) our team began investigating how these compounds could be optimized and made more accessible. According to study available in Science Translational Medicine, November 2012 (Cedars Sinai Medical Center, Los Angeles, Elizabeth A. Martin and others) - tadalafil quickly improved blood flow in 8 out of 9 patients with poor circulation. This effect happened right after just one dose and made a big difference.
This journey led Flex Pharma to explore the broader implications of vessel health and vasodilation - a crucial factor in everything from athletic performance to sexual wellness.
The result is a science-driven approach to bringing trusted generics of these powerful medications to U.S. citizens at a fraction of the cost.
At Flex Pharma, we believe that accessibility starts with transparency and quality. That's why we work exclusively with vetted manufacturers and rigorously tested formulations. Here, every generic product we offer delivers the same efficacy and safety profile as its brand-name counterpart.
The founder of Flex Pharma, Dr. Rod MacKinnon, a professor of molecular neurobiology and biophysics at Rockefeller University